Retrospective analysis of multidrug-resistant Acinetobacter baumannii strains isolated during a 4-year period in a university hospital

Infection Control and Hospital Epidemiology

Volumn 27, Issue 7, 2006, Pages 647-653

  Fillaux, Judith ^a   Dubouix, Anne ^a   Conil, Jean Marie ^a   Laguerre, Jacky ^a   Marty, Nicole ^a,b  

^a CHU RANGUEIL   (France)

^b Institut Federatif de Biologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; NETILMICIN; OFLOXACIN; PEFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BLOOD SAMPLING; CLINICAL FEATURE; CONTROLLED STUDY; FRANCE; INTENSIVE CARE UNIT; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PULSED FIELD GEL ELECTROPHORESIS; UNIVERSITY HOSPITAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; DISEASE OUTBREAKS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; ELECTROPHORESIS, GEL, PULSED-FIELD; EPIDEMIOLOGY, MOLECULAR; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; RETROSPECTIVE STUDIES;

EID: 33747740046     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/507082     Document Type: Article

References (41)

1. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9:148-165.
2. Brown S, Bantar C, Young HK, Amyes SG. Limitation of Acinetobacter baumannii treatment by plasmid-mediated carbapenemase ARI-2. Lancet 1998; 351:186-187.
3. Nordmann P. Acinetobacter baumannii, the nosocomial pathogen par excellence [in French]. Pathol Biol (Paris) 2004; 52:301-303.
4. Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 2002; 8:687-693.
5. Mulin B, Talon D, Viel JF, et al. Risk factors for nosocomial colonization with multiresistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 1995; 14:569-576.
6. Corbella X, Montero A, Pujol M, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000; 38:4086-4095.
7. Lortholary O, Fagon JY, Hoi AB, et al. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis 1995; 20:790-796.
8. Mahgoub S, Ahmed J, Glatt AE. Completely resistant Acinetobacter baumannii strains. Infect Control Hosp Epidemiol 2002; 23:477-479.
9. Fierobe L, Lucet J-C, Decré D, et al. An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect Control Hosp Epidemiol 2001; 22:35-40.
10. Dijkshoorn L, Aucken H, Gerner-Smidt P, et al. Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. J Clin Microbiol 1996; 34:1519-1525.
11. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol 1998; 36:1938-1941.
12. Koeleman JGM, van der Bijl MW, Stoof J, Vandenbroucke-Grauls CMJE, Savelkoul PHM. Antibiotic resistance is a major risk factor for epidemic behavior of Acinetobacter baumannii. Infect Control Hosp Epidemiol 2001; 22:284-288.
13. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000; 31:690-697.
14. Tankovic J, Legrand P, De Gatines G, Chemineau V, Brun-Buisson C, Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J Clin Microbiol 1994; 32:2677-2681.
15. Biendo M, Laurans G, Lefebvre JF, Daoudi F, Eb F. Epidemiological study of an Acinetobacter baumannii outbreak by using a combination of antibiotyping and ribotyping. J Clin Microbiol 1999; 37:2170-2175.
16. Das I, Lambert P, Hill D, Noy M, Bion J, Elliott T. Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units. J Hosp Infect 2002; 50:110-114.
17. Weinbren MJ, Johnson AP, Kaufmann ME, Livermore DM. Acinetobacter spp. isolates with reduced susceptibilities to carbapenems in a UK burns unit. J Antimicrob Chemother 1998; 41:574-576.
18. Health Protection Agency. A prevalent strain of Acinetobacter baumannii. Commun Dis Rep CDR Wkly 2003; 13. Available at: http://www.hpa .org.uk/cdr/archives/2003/cdf2903.pdf. Accessed April 14, 2005.
19. Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother 2000; 44:1556-1561.
20. Herruzo R, de la Cruz J, Fernandez-Acenero MJ, Garcia-Caballero J. Two consecutive outbreaks of Acinetobacter baumannii 1-a in a burn intensive care unit for adults. Burns 2004; 30:419-423.
21. Joly-Guillou ML, Bergogne-Berezin E, Vieu JF. Epidemiology of Acinetobacter and resistance to antibiotics at hospitals: a 5-year evaluation [in French]. Presse Med 1990; 19:357-361.
22. Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993; 167:448-451.
23. Costa SF, Woodcock I, Gill M, et al. Outer-membrane proteins pattern and detection of beta-lactamases in clinical isolates of imipenem-resistant Acinetobacter baumannii from Brazil. Int J Antimicrob Agents 2000; 13:175-182.
24. Afzal-Shah M, Livermore DM. Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 1998; 41:576-577.
25. Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001; 45:583-588.
26. Chu YW, Afzal-Shah M, Houang ET, et al. IMP-4, a novel metallo-beta-lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998. Antimicrob Agents Chemother 2001; 45:710-714.
27. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum beta-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 2003; 41:3542-3547.
28. Institut National de Veille Sanitaire. Enquête de prévalence nationale 2001-résultants: réseau d'alerte d'investigations et de surveillance des infections nosocomiales (RAISIN). Available at: http://www.invs.sante.fr/publications/2003/raisin_enp_2001/index.html. Accessed April 14, 2005.
29. Institut National de Veille Sanitaire. Infections ou colonisations à Acinetobacter baumannii multirésistant aux antibiotiques, France: point sur la situation au 10 février 2004. Available at: http://www.invs.sante.fr/presse/2004/le_point_sur/inf_a_baumanii_110204.html. Accessed April 14, 2005.
30. Institut National de Veille Sanitaire. Réseau d'alerte d'investigations et de surveillance des infections nosocomiales (RAISIN): infections ou colonisations à Acinetobacter baumannii multi-résistant aux antibiotiques, France, juin 2004. Available at: http://www.invs.sante.fr/presse/2004/le_point_sur/inf_a_baumannii_300704/index. html. Accessed April 14, 2005.
31. Heritier C, Dubouix A, Poirel L, Marty N, Nordmann P. A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem- hydrolysing oxacillinase OXA-58. J Antimicrob Chemother 2005; 55:115-118.
32. Société Française de Microbiologie. Comité de l'antibiogramme. Available at: http://www.sfm.asso.fr/. Accessed April 14, 2005.
33. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233-2239.
34. McDonald LC, Banerjee SN, Jarvis WR, Nosocomial Infections Surveillance System. Seasonal variation of Acinetobacter infections: 1987-1996. Clin Infect Dis 1999; 29:1133-1137.
35. Circulaire no. DHOS/ED2-DGS/SD5C no. 21 du 22 janvier 2004 relative au signalement des infections nosocomiales et à l'information des patients dans les établissments de santé. Council order no. 2000-697, July 26, 2001. Paris: Ministère de la santé, de la famille, et des personnes handicapées; 2004.
36. Christie C, Mazon D, Hierholzer W Jr, Patterson JE. Molecular heterogeneity of Acinetobacter baumannii isolates during seasonal increase in prevalence. Infect Control Hosp Epidemiol 1995; 16:590-594.
37. Zarrilli R, Crispino M, Bagattini M, et al. Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol 2004; 42:946-953.
38. Villari P, Iacuzio L, Vozzella EA, Bosco U. Unusual genetic heterogeneity of Acinetobacter baumannii isolates in a university hospital in Italy. Am J Infect Control 1999; 27:247-253.
39. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999; 96:1152-1156.
40. Randegger CC, Keller A, Irla M, Wada A, Hachler H. Contribution of natural amino acid substitutions in SHV extended-spectrum beta-lactamases to resistance against various beta-lactams. Antimicrob Agents Chemother 2000; 44:2759-2763.
41. Perez-Roth E, Lorenzo-Diaz F, Batista N, Moreno A, Mendez-Alvarez S. Tracking methicillin-resistant Staphylococcus aureus clones during a 5-year period (1998 to 2002) in a Spanish hospital. J Clin Microbiol 2004; 42:4649-4656.